REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)

3 Months Ended

Mar. 31, 2022

Concentration Risk And Geographic Information [Abstract]

Schedule of Net Product Revenues by Product

The following table disaggregates total Net Product Revenues by product.

	Three Months Ended March 31,
	2022		2021
Net product revenues by product:
Vimizim	$	183,059	$	158,298
Naglazyme	128,031		107,336
Kuvan	59,337		70,763
Palynziq	54,885		54,038
Brineura	36,173		27,325
Voxzogo	19,658		—
Total net product revenues marketed by the Company	481,143		417,760
Aldurazyme net product revenues marketed by Sanofi	24,382		50,009
Total net product revenues	505,525		467,769
Royalty and other revenues	13,834		18,261
Total revenues	$	519,359	$	486,030

Schedule of Total Net Product Revenues Based on Patient Location

The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for Company's commercial products sold directly by the Company, except for Aldurazyme, which is sold exclusively by Sanofi worldwide.

	Three Months Ended March 31,
	2022		2021
Europe	$	156,832	$	148,872
United States	150,815		155,064
Middle East	65,607		15,559
Latin America	62,544		59,705
Rest of world	45,345		38,560
Total net product revenues marketed by the Company	$	481,143	$	417,760
Aldurazyme net product revenues marketed by Sanofi	24,382		50,009
Total net product revenues	$	505,525	$	467,769

Schedule of Net Product Revenue Concentrations Attributed to Largest Customers

The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. 

	Three Months Ended March 31,
	2022		2021
Customer A	17	%	16	%
Customer B	11	%	12	%
Customer C	8	%	9	%
Customer D	5	%	11	%
Total	41	%	48	%